You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFludrocortisone
Accession NumberDB00687  (APRD00756, DB02478)
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic mineralocorticoid with anti-inflammatory activity. [PubChem]
Structure
Thumb
Synonyms
9alpha-FLUOROCORTISOL
Fludrocortison
Fludrocortisona
Fludrocortisone
Fludrocortisonum
Fluohydrocortisone
External Identifiers
  • StC 1400
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Florineftablet0.1 mgoralPaladin Labs Inc1995-12-31Not applicableCanada
Florinef Acetate 0.1mgtablet.1 mgoralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1958-12-311997-08-14Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fludrocortisone Acetatetablet.1 mg/1oralPhysicians Total Care, Inc.2005-10-06Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralImpax Generics2002-03-18Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralAv Kare, Inc.2002-03-18Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralCardinal Health2008-05-09Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralWest ward Pharmaceutical Corp2011-07-22Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralREMEDYREPACK INC.2011-10-03Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralAmerican Health Packaging2008-05-09Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralBarr Laboratories Inc.2003-02-14Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralAv Pak2011-08-01Not applicableUs
Fludrocortisone Acetatetablet.1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdixoneGenopharm
AstoninMerck
CortineffPolfa Pabianice
Florinef AcetaatBristol-Myers Squibb
FlorinefeBristol-Myers Squibb
FludrocortisonBristol-Myers Squibb
LonikanMerck
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fludrocortisone Acetate
Thumb
  • InChI Key: SYWHXTATXSMDSB-GSLJADNHSA-N
  • Monoisotopic Mass: 422.210466929
  • Average Mass: 422.487
DBSALT000659
Categories
UNIIU0476M545B
CAS number127-31-1
WeightAverage: 380.4504
Monoisotopic: 380.199902243
Chemical FormulaC21H29FO5
InChI KeyInChIKey=AAXVEMMRQDVLJB-BULBTXNYSA-N
InChI
InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
IUPAC Name
(1R,2S,10S,11S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
PharmacodynamicsFludrocortisone is a synthetic adrenocortical steroid possessing very potent mineralocorticoid properties and high glucocorticoid activity. It is indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome. The physiologic action of fludrocortisone acetate is similar to that of hydrocortisone. However, the effects of fludrocortisone acetate, particularly on electrolyte balance, but also on carbohydrate metabolism, are considerably heightened and prolonged. Mineralocorticoids act on the distal tubules of the kidney to enhance the reabsorption of sodium ions from the tubular fluid into the plasma; they increase the urinary excretion of both potassium and hydrogen ions.
Mechanism of actionFludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of the mineralocorticoid receptor by fludrocortisone) in turn causes an increase in ion and water transport and thus raises extracellular fluid volume and blood pressure and lowers potassium levels.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingHigh
Metabolism

Hepatic, some renal.

Route of eliminationNot Available
Half life3.5 hours
ClearanceNot Available
ToxicityEffects of overexposure include irritation, cardiac edema, increased blood volume, hypertension, cardiac arrhythmias, enlargement of the heart, headaches, and weakness of the extremities.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9731
Caco-2 permeable+0.8415
P-glycoprotein substrateSubstrate0.7911
P-glycoprotein inhibitor INon-inhibitor0.8385
P-glycoprotein inhibitor IINon-inhibitor0.9351
Renal organic cation transporterNon-inhibitor0.7774
CYP450 2C9 substrateNon-substrate0.8799
CYP450 2D6 substrateNon-substrate0.909
CYP450 3A4 substrateSubstrate0.7138
CYP450 1A2 substrateNon-inhibitor0.9306
CYP450 2C9 inhibitorNon-inhibitor0.9023
CYP450 2D6 inhibitorNon-inhibitor0.9201
CYP450 2C19 inhibitorNon-inhibitor0.9285
CYP450 3A4 inhibitorNon-inhibitor0.8772
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.903
Ames testNon AMES toxic0.8895
CarcinogenicityNon-carcinogens0.9479
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.1686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9591
hERG inhibition (predictor II)Inhibitor0.5213
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Barr laboratories inc
  • Impax laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral0.1 mg
Tabletoral.1 mg
Tabletoral.1 mg/1
Prices
Unit descriptionCostUnit
Fludrocortisone acetate powder73.14USD g
Florinef acetate 0.1 mg tablet1.49USD tablet
Fludrocortisone Acetate 0.1 mg tablet0.81USD tablet
Fludrocortisone 0.1 mg tablet0.75USD tablet
Florinef 0.1 mg Tablet0.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility140 mg/L (at 25 °C)MERCK INDEX (1996)
logP1.67HANSCH,C ET AL. (1995)
logS-3.43ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.224 mg/mLALOGPS
logP1.35ALOGPS
logP1.32ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity96.93 m3·mol-1ChemAxon
Polarizability39.6 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 2,957,013

General ReferencesNot Available
External Links
ATC CodesS03CA05S02CA07S01CA06H02AA02
AHFS Codes
  • 68:04.00
PDB Entries
FDA labelNot Available
MSDSDownload (73 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with 1,10-Phenanthroline.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Fludrocortisone.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Fludrocortisone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fludrocortisone.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Fludrocortisone.
AldesleukinFludrocortisone may decrease the antineoplastic activities of Aldesleukin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Fludrocortisone.
Aluminum hydroxideThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fludrocortisone.
AmiodaroneThe serum concentration of Fludrocortisone can be increased when it is combined with Amiodarone.
Amphotericin BFludrocortisone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Fludrocortisone can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Fludrocortisone can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fludrocortisone.
BazedoxifeneThe serum concentration of Fludrocortisone can be increased when it is combined with Bazedoxifene.
BendroflumethiazideFludrocortisone may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fludrocortisone.
Bismuth SubcitrateThe bioavailability of Fludrocortisone can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Fludrocortisone can be increased when it is combined with Boceprevir.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Fludrocortisone.
BumetanideFludrocortisone may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fludrocortisone.
Calcium carbonateThe bioavailability of Fludrocortisone can be decreased when combined with Calcium carbonate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fludrocortisone.
CarbamazepineThe serum concentration of Fludrocortisone can be decreased when it is combined with Carbamazepine.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Fludrocortisone.
CeritinibFludrocortisone may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Fludrocortisone can be increased when it is combined with Ceritinib.
ChlorothiazideFludrocortisone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Fludrocortisone can be increased when it is combined with Chlorotrianisene.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fludrocortisone.
ChlorthalidoneFludrocortisone may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Fludrocortisone.
ClarithromycinThe serum concentration of Fludrocortisone can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Fludrocortisone can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Fludrocortisone can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fludrocortisone.
CoumaphosThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Coumaphos.
DarunavirThe serum concentration of Fludrocortisone can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Demecarium.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Fludrocortisone.
DichlorvosThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dichlorvos.
DienestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fludrocortisone.
DihydrotestosteroneFludrocortisone may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Donepezil.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Fludrocortisone.
EchothiophateThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Edrophonium.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fludrocortisone.
EnzalutamideThe serum concentration of Fludrocortisone can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Fludrocortisone can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Fludrocortisone can be increased when it is combined with Estriol.
EstroneThe serum concentration of Fludrocortisone can be increased when it is combined with Estrone.
Etacrynic acidFludrocortisone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Fludrocortisone can be increased when it is combined with Ethinyl Estradiol.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Fludrocortisone.
FenthionThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fenthion.
FingolimodFludrocortisone may increase the immunosuppressive activities of Fingolimod.
FluoxymesteroneFludrocortisone may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Fludrocortisone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fludrocortisone can be decreased when it is combined with Fosphenytoin.
FurosemideFludrocortisone may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Fludrocortisone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ginkgo biloba.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Fludrocortisone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Fludrocortisone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Fludrocortisone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Fludrocortisone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Fludrocortisone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fludrocortisone.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fludrocortisone.
HexestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fludrocortisone.
HydrochlorothiazideFludrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideFludrocortisone may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Fludrocortisone can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Fludrocortisone.
IndapamideFludrocortisone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Fludrocortisone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Fludrocortisone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Fludrocortisone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Fludrocortisone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fludrocortisone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Fludrocortisone.
IsoflurophateThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fludrocortisone.
ItraconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Ketoconazole.
LeflunomideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Leflunomide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Fludrocortisone.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Fludrocortisone.
LopinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Fludrocortisone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fludrocortisone.
MestranolThe serum concentration of Fludrocortisone can be increased when it is combined with Mestranol.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone.
MethyclothiazideFludrocortisone may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneFludrocortisone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneFludrocortisone may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Fludrocortisone can be decreased when used in combination with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Fludrocortisone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Fludrocortisone.
MinaprineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Minaprine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Fludrocortisone.
MitotaneThe serum concentration of Fludrocortisone can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fludrocortisone.
NatalizumabThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Fludrocortisone.
NefazodoneThe serum concentration of Fludrocortisone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Neostigmine.
NevirapineThe serum concentration of Fludrocortisone can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nicorandil.
OxandroloneFludrocortisone may increase the fluid retaining activities of Oxandrolone.
OxymetholoneFludrocortisone may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Fludrocortisone can be decreased when it is combined with Pentobarbital.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Fludrocortisone.
PhenobarbitalThe serum concentration of Fludrocortisone can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fludrocortisone.
PhenytoinThe serum concentration of Fludrocortisone can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Physostigmine.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludrocortisone.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Fludrocortisone.
PiretanideFludrocortisone may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Fludrocortisone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideFludrocortisone may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Fludrocortisone.
PrimidoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pyridostigmine.
QuinestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Quinestrol.
QuinethazoneFludrocortisone may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fludrocortisone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Fludrocortisone.
RifabutinThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Fludrocortisone can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rivastigmine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Fludrocortisone.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Fludrocortisone.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fludrocortisone.
SaquinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Fludrocortisone.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludrocortisone.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Fludrocortisone.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fludrocortisone.
StanozololFludrocortisone may increase the fluid retaining activities of Stanozolol.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Fludrocortisone.
Synthetic Conjugated Estrogens, AThe serum concentration of Fludrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Fludrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludrocortisone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fludrocortisone.
TelaprevirThe serum concentration of Fludrocortisone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Fludrocortisone can be increased when it is combined with Telithromycin.
TestosteroneFludrocortisone may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Fludrocortisone can be increased when it is combined with Tibolone.
TofacitinibFludrocortisone may increase the immunosuppressive activities of Tofacitinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Fludrocortisone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Fludrocortisone.
TorasemideFludrocortisone may increase the hypokalemic activities of Torasemide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Fludrocortisone.
TrichlorfonThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Trichlorfon.
TrichlormethiazideFludrocortisone may increase the hypokalemic activities of Trichlormethiazide.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Fludrocortisone.
TubocurarineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tubocurarine.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fludrocortisone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Fludrocortisone.
VoriconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Voriconazole.
WarfarinFludrocortisone may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Fludrocortisone can be increased when it is combined with Zeranol.
Food Interactions
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Otte C, Jahn H, Yassouridis A, Arlt J, Stober N, Maass P, Wiedemann K, Kellner M: The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sci. 2003 Aug 22;73(14):1835-45. [PubMed:12888122 ]
  2. Oelkers W, Buchen S, Diederich S, Krain J, Muhme S, Schoneshofer M: Impaired renal 11 beta-oxidation of 9 alpha-fluorocortisol: an explanation for its mineralocorticoid potency. J Clin Endocrinol Metab. 1994 Apr;78(4):928-32. [PubMed:8157723 ]
  3. Young MJ, Funder JW: Mineralocorticoids, salt, hypertension: effects on the heart. Steroids. 1996 Apr;61(4):233-5. [PubMed:8733007 ]
  4. Kingsley-Kallesen M, Mukhopadhyay SS, Wyszomierski SL, Schanler S, Schutz G, Rosen JM: The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. Mol Endocrinol. 2002 Sep;16(9):2008-18. [PubMed:12198239 ]
  5. Buckley TM, Mullen BC, Schatzberg AF: The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology. 2007 Sep-Nov;32(8-10):859-64. Epub 2007 Jul 30. [PubMed:17666187 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Trune DR, Kempton JB: Low dose combination steroids control autoimmune mouse hearing loss. J Neuroimmunol. 2010 Dec 15;229(1-2):140-5. doi: 10.1016/j.jneuroim.2010.07.026. Epub 2010 Aug 30. [PubMed:20800906 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:
AR
Uniprot ID:
P10275
Molecular Weight:
98987.9 Da
References
  1. Krishnan AV, Zhao XY, Swami S, Brive L, Peehl DM, Ely KR, Feldman D: A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology. 2002 May;143(5):1889-900. [PubMed:11956172 ]
  2. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P: Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem. 2002 Mar 28;45(7):1439-46. [PubMed:11906285 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23